Malignant neoplasm of the bladder — DVA SoP factors

Reasonable Hypothesis (RH) — Statement of Principles No. 83 of 2019

At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the bladder or death from malignant neoplasm of the bladder with the circumstances of a person's relevant service:

1. (1)
   smoking at least 2.5 pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of malignant neoplasm of the bladder, where smoking commenced at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 - Dictionary.

2. (2)
   having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the bladder at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.

3. (3)
   inhaling, ingesting or having cutaneous contact with high concentrations of polycyclic aromatic hydrocarbons, through work involving the specified industrial or manufacturing process 1: (a) for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the bladder; and (b) where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: polycyclic aromatic hydrocarbons and specified industrial or manufacturing process 1 are defined in the Schedule 1 - Dictionary.

4. (4)
   inhaling, ingesting or having cutaneous contact with an agent from the specified list of agents containing high concentrations of polycyclic aromatic hydrocarbons: (a) for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the bladder; and (b) where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: specified list of agents containing high concentrations of polycyclic aromatic hydrocarbons is defined in the Schedule 1 - Dictionary.

5. (5)
   inhaling, ingesting or having cutaneous contact with an aromatic amine from the specified list of aromatic amines: (a) for a cumulative period of at least 1 000 hours, before the clinical onset of malignant neoplasm of the bladder; and (b) where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: Inhaling, ingesting or having cutaneous contact with an aromatic amine does not include exposure due to cigarette smoke or hair dyes.

   Note: specified list of aromatic amines is defined in the Schedule 1 - Dictionary.

6. (6)
   inhaling, ingesting or having cutaneous contact with a high concentration of an aromatic amine, through work involving the specified industrial or manufacturing process 2: (a) for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the bladder; and (b) where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;

   Note: Inhaling, ingesting or having cutaneous contact with a high concentration of an aromatic amine does not include exposure due to cigarette smoke or hair dyes.

   Note: specified industrial or manufacturing process 2 is defined in the Schedule 1 - Dictionary.

7. (7)
   inhaling, ingesting or having cutaneous contact with tetrachloroethylene for a cumulative period of at least 5 000 hours before the clinical onset of malignant neoplasm of the bladder, where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;
8. (8)
   inhaling, ingesting or having cutaneous contact with a high concentration of 2-mercaptobenzothiazole for a cumulative period of at least 1 500 hours before the clinical onset of malignant neoplasm of the bladder, where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;
9. (9)
   being heavily exposed to diesel engine exhaust for a cumulative period of at least 15 000 hours, before the clinical onset of malignant neoplasm of the bladder;

   Note: being heavily exposed to diesel engine exhaust is defined in the Schedule 1 - Dictionary.

10. (10)
    being exposed to lead as specified before the clinical onset of malignant neoplasm of the bladder, where the first exposure occurred at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: being exposed to lead as specified is defined in the Schedule 1 - Dictionary.

11. (11)
    being exposed to arsenic as specified before the clinical onset of malignant neoplasm of the bladder, where the first exposure to arsenic occurred at least ten years before the clinical onset of malignant neoplasm of the bladder;

    Note: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary.

12. (12)
    working as a hairdresser or barber for a cumulative period of at least 5 000 hours before the clinical onset of malignant neoplasm of the bladder, where that work began at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: working as a hairdresser or barber is defined in the Schedule 1 - Dictionary.

13. (13)
    working as a painter for a cumulative period of at least 5 000 hours before the clinical onset of malignant neoplasm of the bladder, where that work began at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: working as a painter is defined in the Schedule 1 - Dictionary.

14. (14)
    having renal stone disease or a bladder stone at least five years before the clinical onset of malignant neoplasm of the bladder;
15. (15)
    having chronic renal failure at least one year before the clinical onset of malignant neoplasm of the bladder;

    Note: chronic renal failure is defined in the Schedule 1 - Dictionary.

16. (16)
    having an infection of the bladder with Schistosoma haematobium at least five years before the clinical onset of malignant neoplasm of the bladder;
17. (17)
    having an indwelling bladder catheter or other foreign body in the bladder for a continuous period (excepting routine catheter changes) of at least five years, before the clinical onset of malignant neoplasm of the bladder;
18. (18)
    having neurogenic bladder at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: neurogenic bladder is defined in the Schedule 1 - Dictionary.

19. (19)
    having chronic urinary tract infection at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: chronic urinary tract infection is defined in the Schedule 1 - Dictionary.

20. (20)
    having diabetes mellitus for at least five years before the clinical onset of malignant neoplasm of the bladder;
21. (21)
    having benign prostatic hyperplasia at least five years before the clinical onset of malignant neoplasm of the bladder;
22. (22)
    ingesting aristolochic acid as specified at least two years before the clinical onset of malignant neoplasm of the bladder;

    Note: ingesting aristolochic acid as specified is defined in the Schedule 1 - Dictionary.

23. (23)
    consuming a total of at least 100 grams of phenacetin at least five years before the clinical onset of malignant neoplasm of the bladder;

    Note: phenacetin is defined in the Schedule 1 - Dictionary.

24. (24)
    being treated with systemic cyclophosphamide or systemic ifosfamide, at least five years before the clinical onset of malignant neoplasm of the bladder;
25. (25)
    being treated with chlornaphazine at least five years before the clinical onset of malignant neoplasm of the bladder;
26. (26)
    being treated with pioglitazone, or a medication containing pioglitazone, for a continuous period of at least one year, within the ten years before the clinical onset of malignant neoplasm of the bladder;
27. (27)
    taking opium on average at least weekly for at least ten years before the clinical onset of malignant neoplasm of the bladder;
28. (28)
    inability to obtain appropriate clinical management for malignant neoplasm of the bladder;

Aggravation-only factors: the factors in subsection 9(28) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.